Apert and Crouzon syndromes: Clinical findings, genes and extracellular matrix

Journal of Craniofacial Surgery

Volumn 16, Issue 3, 2005, Pages 361-368

  Carinci, Francesco ^a,b,h   Pezzetti, Furio ^a,c   Locci, Paola ^a,d   Becchetti, Ennio ^a,e   Carls, Friedrick ^a   Avantaggiato, Anna ^a,b   Becchetti, Alessio ^a,e,f   Carinci, Paolo ^a,c,g   Baroni, Tiziano ^a,e   Bodo, Maria ^a,e  

^a University of Ferrara ^*

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d University of Terni   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f JRH   (United Kingdom)

^g CARISBO Foundation   (Italy)

^h UNIVERSITY OF FERRARA   (Italy)

Author keywords

Apert syndrome; Craniosynostosis; Crouzon syndrome; Extracellular matrix; Gene

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLYCOSAMINOGLYCAN; PROTEIN;

ACROCEPHALOSYNDACTYLY; ARTICLE; AUTOCRINE EFFECT; AUTOSOMAL DOMINANT INHERITANCE; BINDING AFFINITY; CELL SECRETION; CROUZON SYNDROME; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING;

ACROCEPHALOSYNDACTYLIA; AMINO ACID SUBSTITUTION; CRANIOFACIAL DYSOSTOSIS; EXTRACELLULAR MATRIX; GENES, DOMINANT; HUMANS; OSTEOGENESIS; POINT MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 20744456449     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SCS.0000157078.53871.11     Document Type: Article

References (52)

1. Apert M. De l'acrocephalosyndactylie. Bull Mem Soc Med Hop Paris 1906;23:1310-1330
2. Avantaggiato A, Carinci F, Curioni C. Apert syndrome: cephalometric evaluation and considerations on pathogenesis. J Craniofac Surg 1996;7:23-31
3. Blank C. Apert syndrome (a type of acrocephalosyndactyly): observations on a British series of thirty-nine cases. Ann Hum Genet 1960;24:151-164
4. Gorlin R, Cohen M, Levin L. Syndromes with craniostenosinostopsys: general aspects and well-known syndromes. In: Gorlin R, Cohen M, Levin L, eds. Syndromes of the head and neck. Oxford: Oxford University Press, 1990:520-526
5. Patton M, Goodship J, Hayward R, Lansdown R. Intellectual development in Apert syndrome: a long term follow up of 29 patients. J Med Genet 1988;25:164-167
6. Cohen M, Kreiborg S. The central nervous system in the Apert syndrome. Am J Med Genet 1990;35:36-45
7. Reiner D, Arnaud E, Cinalli G, et al. Prognosis for mental function in Apert syndrome. J Neurosurg 1996;85:66-72
8. Kreiborg A, Barr M, Cohen M. Cervical spine in the Apert syndrome. Am J Med Genet 1992;43:704-708
9. Cohen M, Kreiborg S. Cutaneous manifestations of Apert syndrome. Am J Med Genet 1995;58:94-96
10. Vogt A. Dyskephalie (dysostosis craniofacialis, maladie De Crouzon 1912) und eine neuartige Kombination dieser Krankheit mit Syndaktylie der 4 Extremitaeten (Dyskephalodaktylie). Klin Mbl Augenheilk 1933;90:441-454
11. Nager F, de Reynier J. Das Gehoerorgan bei den angeborenen Kopfmissbildungen. Pract Otorhinolaryng 1948;10(Suppl 2): 1-128
12. Wilkie A, Slaney S, Oldridge M, et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nature Genet 1995;9:165-172
13. Gilbert E, Del Gatto F, Champion-Arnaud P, et al. Control of BEK and K-SAM splice sites in alternative splicing of the fibroblast growth factor receptor 2 pre-mRNA. Molec Cell Biol 1993; 13:5461-5468
14. Slaney S, Oldridge M, Hurst J, et al. Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. Am J Hum Genet 1996;58:923-932
15. Oldridge M, Lunt P, Zackai E, et al. Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2. Hum Molec Genet 1997;6:137-143
16. Moloney D, Slaney S, Oldridge M, et al. Exclusive paternal origin of new mutations in Apert syndrome. Nature Genet 1996; 13:48-53
17. Van Dissel-Emiliani F, De Boer-Brouwer M, De Rooij D. Effect of fibroblast growth factor-2 on Sertoli cells and gonocytes in co-culture during the perinatal period. Endocrinology 1996;137: 647-654
18. Oldridge M, Zackai E, McDonald-McGinn D, et al. De novo Alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. Am J Hum Genet 1999;64: 446-461
19. Lajeunie E, Cameron R, El Ghouzzi V, et al. Clinical variability in patients with Apert syndrome. J Neurosurg 1999;90:443-447
20. von Gernet S, Golla A, Ehrenfels Y, et al. Genotype-phenotype analysis in Apert syndrome suggests opposite effects of the two recurrent mutations on syndactyly and outcome of craniofacial surgery. Clin Genet 2000;57:137-139
21. Munro C, Wilkie A. Epidermal mosaicism producing localised acne: somatic mutation in FGFR2. Lancet 1998;352:704-705
22. Jackson R. The lines of Blaschko: a review and reconsideration. Br J Derm 1976;95:349-360
23. Shuster S. Dermatology in Clinical Medicine. Oxford: Oxford University Press, 1978
24. Anderson J, Burns H, Enriquez-Harris P, et al. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Molec Genet 1998;7: 1475-1483
25. Yu K, Herr A, Waksman G, Ornitz D. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Nat Acad Sci 2000;97:14536-14541
26. Bodo M, Carinci F, Baroni T, et al. Apert syndrome: differential in vitro production of matrix macromolecules and its regulation by interleukins. Eur J Clin Invest 1997;27:36-42
27. Bodo M, Carinci F, Baroni T, et al. Interleukin pattern of Apert fibroblasts in vitro. Eur J Cell Biol 1998;75:383-388
28. Locci P, Baroni T, Pezzetti F, et al. Differential in vitro phenotype pattern, transforming growth factor-beta(1) activity and mRNA expression of transforming growth factor-beta(1) in Apert osteoblasts. Cell Tissue Res 1999;297:475-483
29. Lomri A, Lemonnier J, Hott M, et al. Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest 1998;101:1310-1317
30. Pellegrini L, Burke D, von Delft F, et al. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000;407:1029-1034
31. Crouzon O. Dysostose cranio-faciale hereditaire. Bull Mem Soc Med Hop Paris 1912;33:545-555
32. Carinci F, Avantaggiato A, Curioni C. Crouzon syndrome: cephalometric analysis and evaluation of pathogenesis. Cleft Palate Craniofac J 1994;31:201-209
33. Kreiborg S. Crouzon syndrome. Scand J Plast Reconstr Surg 1918;18:1-198
34. Dodge H, Wood M, Kennedy R. Craniofacial dysostosis: Crouzon disease. Pediatrics 1959;23:98-106
35. Vulliamy D, Normandale P. Cranio-facial dysostosis in a Dorset family. Arch Dis Child 1966;41:375-382
36. Juberg R, Chambers S. An autosomal recessive form of cranio-facial dysostosis (the Crouzon syndrome). J Med Genet 1973;10: 89-93
37. Franceschetti A. Dysostose cranienne avec calotte cerebriforme (pseudo-Crouzon). Confin Neurol 1953;13:161-166
38. Reardon W, Winter R, Rutland P, et al. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nature Genet 1994;8:98-103
39. Preston R, Post J, Keats B, et al. A gene for Crouzon craniofacial dysostosis maps to the long arm of chromosome 10. Nature Genet 1994;7:149-153
40. Jabs E, Li X, Scott A, et al. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nature Genet 1994;8:275-279
41. Meyers G, Day D, Goldberg R, et al. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 1996;58: 491-498
42. Lajeunie E, Ma H, Bonaventure J, et al. FGFR2 mutations in Pfeiffer syndrome (Letter). Nature Genet 1995;9:108
43. Rutland P, Pulleyn L, Reardon W, et al. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nature Genet 1995;9:173-176
44. Steinberger D, Reinhartz T, Unsold R, Muller U. FGFR2 mutation in clinically nonclassifiable autosomal dominant craniosynostosis with pronounced phenotypic variation. Am J Med Genet 1996;66:81-86
45. Mulvihill J. Craniofacial syndromes: no such thing as a single gene disease. Nature Genet 1995;9:101-103
46. Glaser R, Jiang W, Boyadjiev S, et al. Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome and Pfeiffer syndrome. Am J Hum Genet 2000;66:768-777
47. Carinci F, Bodo M, Tosi L, et al. Expression profiles of craniosynostosis-derived fibroblasts. Mol Med 2002;8:638-644
48. Bodo M, Carinci F, Baroni T, et al. Effects of interleukins on Crouzon fibroblast phenotype in vitro. Release of cytokines and IL-6 mRNA expression. Cytokine 1996;8:772-783
49. Bodo M, Baroni T, Carinci F, et al. A regulatory role of fibroblast growth factor in the expression of decorin, biglycan, betaglycan and syndecan in osteoblasts from patients with Crouzon syndrome. Eur J Cell Biol 1999;78:323-330
50. Bodo M, Baroni T, Carinci F, et al. Interleukin secretion, proteoglycan and procollagen alpha(1) (I) gene expression in Crouzon fibroblasts treated with basic fibroblast growth factor. Cytokine 2000;12:1280-1283
51. Baroni T, Lilli C, Marinucci L, et al. Crouzon syndrome: differential in vitro secretion of bFGF, TGFbeta isoforms and extracellular matrix macromolecules in patients with FGFR2 gene mutation. Cytokine 2002;19:94-98
52. Bodo M, Lilli C, Aisa MC, et al. Basic fibroblast growth factor: effects on matrix remodeling, receptor expression, and transduction pathway in human periosteal fibroblasts with FGFR2 gene mutation. J Interferon Cytokine Res 2002;22:621-630